Circulation. 1997;96:1605-1611
(Circulation. 1997;96:1605-1611.)
© 1997 American Heart Association, Inc.
Major Histocompatibility Complex Class II Antigen Expression in Rejecting Cardiac Allografts
Detection Using In Vivo Imaging With Radiolabeled Monoclonal Antibody
A. Iain McGhie, MD;
Branislav Radovancevic, MD;
Pavel Capek, MD;
Warren H. Moore, MD;
Leela Kasi, PhD;
Lamk Lamki, MD;
Fred J. Clubb, Jr, DVM, PhD;
O. Howard Frazier, MD;
;
James T. Willerson, MD
From the University of Texas Houston Medical School (A.I.M., L.L.,
O.H.F., J.T.W.), Texas Heart Institute/St Luke's Episcopal Hospital
(B.R., P.C., F.J.C., O.H.F., J.T.W.), and Baylor College of Medicine (W.H.M.),
Houston, Tex.
Correspondence to A. Iain McGhie, MD, University of Texas Houston Medical School, Department of Internal Medicine (Cardiology Division), 6431 Fannin, Room 1.228 MSB, Houston, TX 77225. E-mail mcghie{at}heart.med.uth.tmc.edu
 |
Abstract
|
|---|
Background Increased expression of major
histocompatibility
complex class II (MHC-II) antigen occurs during
cardiac allograft
rejection. We tested the hypotheses that (1)
radiolabeled antibody
to MHC-II antigen allows detection of cardiac
allograft rejection
using nuclear imaging techniques and (2) uptake of
radiolabeled
antibody to MHC-II antigen correlates with severity of
rejection.
Methods and Results Thirteen beagles with cervical cardiac
allografts were studied for 64±23 days by use of myocardial biopsy and
in vivo imaging. Uptake of radiolabeled (131I [n=2],
123I [n=1], or 111In [n=10]) antibody to
MHC-II increased over baseline in 7 animals that developed
histological evidence of progressively worsening
allograft rejection (group A), from 72.2±46.1 to 176.8±102.0
counts/pixel/mCi (P<.009). In 4 beagles without
progressively worsening allograft rejection (group B), uptake was
unchanged during follow-up (74.4±43.8 and 60.2±37.4 counts/pixel/mCi;
P=NS). In animals studied with 111In-labeled
antibody, uptake increased from 102.9±23.1 at baseline to 233.2±82.7
counts/pixel/mCi at follow-up in group A animals (P=.036),
with no significant change in group B (91.1±34.9 and 75.9±24.9
counts/pixel/mCi; P=NS). Uptake of 111In-labeled
antibody was 107.5±35.7, 135.9±70.8, and 307.8±90.1 counts/pixel/mCi
in biopsy samples showing evidence of mild, moderate, and severe
rejection, respectively (P=.001). Biopsy samples showing
mild, moderate, and intense MHC-II expression antibody uptake had
uptakes of 92.6±36.3, 158.5±54.7, and 307.8±90.1 counts/pixel/mCi,
respectively (P=.00004).
Conclusions Radiolabeled monoclonal antibodies to MHC-II
antigen can detect cardiac allograft rejection in this large mammal
model of cardiac allograft transplantation, and this technique may have
a potential role in the detection of rejection in patients after
cardiac transplantation.
Key Words: transplantation rejection radioisotopes imaging immunology
 |
Introduction
|
|---|
Survival
after cardiac transplantation has consistently improved
during
the last decade, with current 1- and 5-year survival
rates of 80% to
90% and 60% to 70%, respectively.
1 This has
led to the
increasing use of cardiac transplantation in the
management of patients
with end-stage cardiac disease. Despite
the availability of improved
immunosuppressive agents, one of
the most important clinical problems
in the posttransplant period
is detection and management of rejection.
At present, detection
and quantification of cardiac allograft
rejection require serial
endomyocardial biopsies to
obtain tissue for histological
analysis.
2 Typically,
endomyocardial biopsies are performed weekly for
the
first 4 to 8 weeks after transplantation and progressively reduced
in
frequency over the next few months to 3 to 4 biopsies per
year.
3 These invasive procedures are costly and prone to
sampling
errors.
4 In addition,
histological interpretation is subjective
and, to a
certain extent, arbitrary.
Rejection is associated with upregulation of the adhesion receptors
belonging to the immunoglobulin superfamily, including the major
histocompatibility complex (MHC) class II antigens.5 6 The
increased expression of MHC class II antigens during rejection is seen
in the graft endothelium and on infiltrating
mononuclear cells. Isobe et al,7 using a murine model of
cardiac transplantation, were the first to show that it was feasible to
detect cardiac rejection with 111In-labeled monoclonal
antibodies. One limitation of this model is that unlike larger mammals,
including humans, rejection in mice is primarily provoked by MHC class
I antigens, not class II antigens, and spontaneous long-term tolerance
has been reported in murine graft models in the presence of class II
mismatching.8 For this reason, we believed it was
important to evaluate this technique further using an animal model in
which the pathophysiology of graft rejection more closely
paralleled that found in patients. In addition, we wanted to apply
the technique of immunoscintigraphy to the serial
evaluation of cardiac allografts for longer periods of time, allowing
evaluation of the cardiac allograft under conditions of varying
immunosuppression and degrees of rejection.
Therefore, we used a canine model of cardiac transplantation to test
the hypotheses that (1) abnormal expression of MHC class II antigens
can be detected noninvasively in rejecting allografts with the use of
radiolabeled monoclonal antibodies and (2) detection of abnormal
expression of MHC class II antigens correlates with the
histological severity of rejection in cardiac
allografts.
 |
Methods
|
|---|
Surgical Preparation
The surgical technique involved the transplantation of the
cardiac
allograft into the recipient's neck.
9 The
surgical anatomy
of this nonworking cardiac allograft is
illustrated schematically
in Fig 1

.
Thirteen conditioned beagles (weighing 10 to 15 kg
each) received
heterotopic cardiac allografts from outbred puppy
donors (weighing 2 to
4 kg each). Donor and recipient were premedicated
with acepromazine
maleate (0.1 to 0.2 mg/kg) and oxymorphone
(0.05 mg/kg).
Anesthesia was induced with intravenous
thiopental
sodium (5 to 15 mg/kg) and maintained with isoflurane
(0.5%
to 2.5%), which was delivered through a volume-controlled
ventilator.
Muscle paralysis was provided with pancuronium (0.02 to
0.06
mg/kg IV). The donor heart was harvested through a median
sternotomy.
After preliminary dissection and heparinization (5000 U),
the
heart was arrested with cold potassium cardioplegic solution.
After
explantation, the heart was prepared for implantation
by ligation of
the pulmonary veins and inferior and superior
vena
cavae. The recipients' hearts were prepared by isolating
and exposing
the left common carotid artery and external jugular
vein and by
creating a small cervical skin pocket. After this,
a median sternotomy
and preliminary dissection were performed,
followed by
intravenous heparinization. The graft was then implanted
into
the recipient's neck, with the donor ascending aorta anastomosed
end
to side with the recipient's common carotid artery and the donor
pulmonary
artery anastomosed end to end with the recipient's
external
jugular vein. After reperfusion, hearts were defibrillated and
implanted
into the previously prepared cervical pocket.
Cyclosporin A
was given starting 2 days before
transplantation at a dose of
20 mg/kg and was resumed on the
first postoperative day. Prednisolone
(2 mg/kg) was also given 2
days before transplantation and restarted
on the following day. Varying
degrees of graft rejection were
obtained by gradual reductions in the
prednisolone and cyclosporine
dosages using serum
cyclosporine levels and clinical indicators.
All animals
used in the study received humane care in compliance
with the
"Principles of Laboratory Animal Care" formulated by
the National
Society for Medical Research and the
Guide for the Care and Use
of Laboratory Animals prepared by the National
Academy of Sciences
(NIH publication No. 85-23, revised 1985).

View larger version (54K):
[in this window]
[in a new window]
|
Figure 1. Schematic diagram of surgical preparation. AO
indicates aorta; PA, pulmonary artery; RA, right atrium; LA,
left atrium; CS, coronary sinus; RV, right ventricle; LV, left
ventricle; and Ext., external. See text for further details.
|
|
Pathological Evaluation
Rejection was evaluated by serial percutaneous
transmyocardial biopsies. Two to three tissue samples were obtained at
each time point. Some were fixed in formalin and stained with
hematoxylin and eosin for microscopic evaluation and the remainder were
snap-frozen after embedding in OCT compound (Ames). After the final
image acquisition, the animals were killed and their hearts excised and
processed for subsequent histological analysis.
Representative sections of the right and left
ventricles were selected and stained with hematoxylin and eosin. Tissue
was also frozen and processed for immunohistochemistry. The degree of
cellular rejection was evaluated according to previously published
criteria using both the Texas Heart Institute (THI) and the
International Society of Heart Transplantation (ISHT)
gradations.10 11 The scoring of each section was performed
in a blinded manner by an experienced cardiac pathologist. Sections for
immunohistochemistry were cut at 5-mm intervals at -20°C in a
cryostat, transferred to slides precoated with
poly-D-lysine (Sigma Chemical Co), and fixed in cold
acetone for 10 minutes. These slides were washed twice with PBS, pH
7.4, and then immersed in a 0.1% sodium azide with 1% hydrogen
peroxide in water for 15 minutes at room temperature to neutralize
endogenous peroxidase activity. The slides were then rinsed
twice in PBS and flooded with RPMI 1640 media containing 5% horse
serum. Sections were incubated for 60 minutes with primary mouse
antibody against MHC class II antigen in a moist chamber followed by a
predetermined optimum concentration of biotinylated anti-mouse Ig,
followed by horseradish peroxidase avidin-biotin complexes (Vector
Labs). The sites of antigen/antibody reaction were detected with the
use of 3,3 diaminobenzidine (Sigma). The slides were counterstained
with Mayer's hematoxylin solution, coverslips were put on, and the
slides were then examined under the microscope. Negative control slides
were treated in an identical way except the primary monoclonal antibody
was omitted. Frozen sections of dog lymph node served as a positive
control. Findings were graded in a similar fashion to the THI grading
scale: 0 (negative) and from 1 to 10 (positive). Scoring of the
sections was performed by the same cardiac pathologists who scored the
light microscopic slides.
Immunoscintigraphy
A monoclonal antibody (TH14B; VMRD, Inc) to canine MHC class II
antigens was used. This monomorphic IgG2a monoclonal antibody, which
was obtained from mouse ascites fluid and purified by
centrifugation and filtration through a
0.22-mmol/L filter, was originally developed by Davis et
al.12 13 14 Radioiodination of intact monoclonal antibody
(0.5 to 1.0 mg) was performed with 5 to 10 mCi of either
131I (n=2; DuPont) or 123I (n=1; Nordion) by
incubation in a sterile vial coated with 1 mg Iodo-gen (Pierce Chemical
Co).15 Alternatively, when 111In chloride
(n=10) was used, a DTPA conjugation technique was used.16
Quality control assays included tests for protein-bound iodine
(trichloroacetic acid precipitation), labeling efficiency by instant
thin-layer chromatography in saline. The final
product had a labeling efficiency and protein-bound iodine that
were both >90%.
Beagles were imaged at baseline during full immunosuppression,
2
weeks after transplantation, and at least once thereafter at the end of
the study period. On the day of percutaneous biopsy,
the animals were injected intravenously with radiolabeled
monoclonal antibody and imaged 48 hours after administration of
123I- and 111In-labeled antibodies and 72 hours
after 131I-labeled antibody. Planar images were acquired in
the anterior and left lateral projections. Each image was acquired
for 900 seconds by use of a commercially available single-headed,
rotating
-camera equipped with the appropriate collimator with 20%
windows centered on the relevant photo peaks of the isotope used. After
acquisition of the immunoscintigraphic images, 4 to 6 mCi of
99mTc-labeled sestamibi was injected to verify the location
of native and donor hearts. Regions of interest were drawn in the left
lateral immunoscintigraphic images around the donor and native hearts.
Background regions of interest were generated for both the donor and
native hearts. For the donor heart, the background region of interest
(2 to 3 pixels wide) was drawn adjacent to the anterior wall and apex.
For the native heart, the background region of interest was drawn in
the adjacent lung. Activity in the donor and native hearts was
expressed as counts per pixel corrected for injected dose, background
activity, and decay.
Statistical Analysis
Results are expressed as mean±SD. Paired comparisons were made
by use of paired Student's t tests. ANOVA was used for
multiple comparisons between groups. A value of P<.05 was
considered statistically significant.
 |
Results
|
|---|
A total of 13 animals were studied. Two animals were studied
by
use of
131I-labeled antibody and 1 was studied with
123I-labeled
antibody. The remainder were studied by use of
111In-labeled
antibody because of the suboptimal quality of
images obtained
using radioiodinated antibodies. Two of 10
animals studied by
use of
111In labeling were excluded from
analysis. One animal
rapidly developed clinical evidence of
rejection and died suddenly
before follow-up imaging could be
performed. Another developed
an area of regional akinesia, was found to
have evidence of
regional transmural infarction at autopsy, and was
also excluded
from analysis. In a third animal, intense
activity was noted
on baseline imaging without clinical or
histological evidence
of rejection. This activity
was not present 2 weeks later. The
reason for the transient
increase in activity is unclear, but
it may have resulted from
pericardial reaction, and therefore
these data were not included in the
subsequent analysis.
In the remaining animals (both radioiodinated and
111In-labeled antibody), seven developed progressively
worsening cardiac allograft rejection (group A); the remaining four
animals showed no or minimal progression of allograft rejection
(Table
). The animals in group A showed a
significant increase in the amount of uptake of radiolabeled antibody
to MHC class II antigen, increasing from 72.2±46.1 at baseline to
176.8±102.0 counts/pixel/mCi at the end of the study period
(P<.009). In contrast, the animals in group B showed no
significant change in uptake (74.4±43.8 and 60.2±37.4
counts/pixel/mCi, respectively; P=NS).
Fig 2
summarizes the data obtained using
111In-labeled monoclonal antibody to MHC class II antigen.
In group A animals (n=5), the uptake increased from 102.9±23.1 at
baseline to 233.2±82.7 counts/pixel/mCi at the time of
follow-up (P=.036). In group B animals (n=3), there was no
significant change in the uptake of 111In-labeled antibody
(91.1±34.9 and 75.9±24.9 counts/pixel/mCi, respectively;
P=NS). Image quality was generally good, with rejecting
allografts being easily visualized when 111In-labeled
antibody was used (mean donor target-to-background ratio of 5.3±5.1).
The amount of activity in the region of the native heart was minimal
and often equal to or less than background activity in the adjacent
lung (Table
; Figs 3
and 4
).

View larger version (24K):
[in this window]
[in a new window]
|
Figure 3. Images showing uptake of 111In-labeled
monoclonal antibody to major histocompatibility complex class II
antigens at two different time intervals. Left, Image taken 21 days
after transplantation, showing mild diffuse uptake with a biopsy sample
showing Texas Heart Institute (THI) grade 3. Right, Image obtained 34
days after transplantation, revealing more intense uptake with a
corresponding biopsy sample showing THI grade 7 changes
consistent with moderate rejection.
|
|

View larger version (92K):
[in this window]
[in a new window]
|
Figure 4. Images from an animal with moderate to severe
cardiac allograft rejection. Top left, Image showing an anterior
projection; top right, image showing a left lateral projection.
Bottom right, Corresponding biopsy sample from the transplanted heart;
bottom left, corresponding immunohistochemical section. See text for
further details. Bar, 5 µm.
|
|
Figs 3
and 4
show representative
111In-labeled images. Fig 3
shows uptake of labeled
antibody to MHC class II antigens at two different time intervals. The
image on the left, taken 21 days after transplantation and having a
biopsy sample showing THI grade 3 rejection, shows mild diffuse uptake.
The right-hand image was obtained 34 days after transplantation; it
reveals more intense uptake in the graft, with a corresponding biopsy
sample showing THI grade 7 changes consistent with moderate
rejection. Fig 4
shows images with corresponding biopsy samples from an
animal with moderate rejection (THI grade 7). There is diffuse uptake
of radiolabeled antibody in the donor heart, with minimal residual
blood pool activity seen in the region of the native heart. The
histological sections show marked cellular infiltration
with interstitial mononuclear cells and evidence of myocyte
degeneration, and the immunohistochemically processed section shows
fairly intense expression of MHC class II antigen occurring in the
presence of moderate rejection.
Fig 5
summarizes the relationship between
uptake of 111In-labeled monoclonal uptake and
histological severity of rejection from the
corresponding myocardial biopsy samples. Using the THI grading scale,
we graded biopsy samples as showing mild (grades 1 to 3), moderate
(grades 4 to 8), and severe (grades 9 and 10) degrees of rejection and
compared them with uptake of 111In-labeled antibody (Fig 5A
). Uptake was 107.5±35.7, 135.9±70.8, and 307.8±90.1
counts/pixel/mCi in biopsy samples showing evidence of mild,
moderate, and severe rejection, respectively (P=.001).
Uptake of 111In-labeled antibody was also evaluated using
the ISHT histological gradation scale (Fig 5B
). For
ISHT grades 1A, 1B, 2, 3A, 3B, and 4, uptake was 112.4±54.0,
98.8±18.9, 115.5±96.1, 134.3±56.8, 179.0±23.2, and 307.8±90.1
counts/pixel/mCi, respectively (P=.015). The
relationship between uptake of radiolabeled monoclonal antibody and
intensity of the immunohistological expression of MHC
class II antigens was closer. Uptake in biopsy samples showing mild,
moderate, and intense MHC class II antigen expression was 92.6±36.3,
158.5±54.7, and 307.8±90.1, respectively (P=.00004; Fig 5C
).

View larger version (25K):
[in this window]
[in a new window]
|
Figure 5. Relationship between uptake of
111In-labeled monoclonal antibody and biopsy findings. A,
Texas Heart Institute histological severity of
rejection; B, International Society of Heart Transplantation
histological severity of rejection; C,
immunohistological severity of rejection. Values are
expressed as mean counts per pixel corrected for background activity
and decay (cts/pixel/mCi); see text for further
details.
|
|
 |
Discussion
|
|---|
Noninvasive Detection of Cardiac Rejection
Many techniques have been evaluated for noninvasively detecting
rejection
after cardiac transplantation. Currently, no noninvasive
technique
has found widespread acceptance for use in the
detection of
rejection in patients after cardiac transplantation.
Several
studies have shown that moderate to severe rejection after
cardiac
allograft transplantation can be detected with the use of a
radiolabeled
monoclonal antibody to myosin both in experimental
models
17 18 19 20 and in patients.
21 22 These
studies have shown a
variable correlation between scintigraphic
findings using
111In-labeled
anti-myosin antibody and the
histological extent of myocyte
necrosis after
transplantation. In patients with cardiac allografts,
radiolabeled
anti-myosin antibody uptake is reported to have
a reasonable
sensitivity (range, 80% to 95%), with a somewhat
more questionable
specificity (range, 33% to 80%).
MHC Class II Antigen Expression in Cardiac Rejection
The immunoglobulin superfamily of adhesion receptors, including
the MHC class II antigens, plays an important role in the
pathophysiology of allograft rejection.23 24
Immunocytochemical techniques have allowed identification of the
different types of mononuclear cells associated with rejection and
their interaction with antigens expressed on the graft. These
techniques have revealed intense expression of MHC class II antigens in
endomyocardial biopsy samples from patients with
cardiac allograft rejection.5 6
Isobe et al,7 using a murine model of cardiac
transplantation, were the first to show that it was possible to detect
cardiac rejection using radiolabeled antibodies to murine equivalent
MHC class II antigens. However, unlike in larger mammals, rejection in
mice is primarily provoked by MHC class I antigens, not class II
antigens, and spontaneous long-term tolerance has been reported using a
murine vascularized graft model in the presence of class II
mismatching.8 In the present study, we demonstrated
that the upregulation of MHC class II antigen expression that occurs
during rejection can be imaged successfully in this larger mammal in
which MHC class II antigens are primarily responsible for rejection, as
occurs in humans. In addition, by studying animals for a period of
months, we were able to show that detection of increasing uptake of
radiolabeled antibody to MHC class II antigen by the cardiac allograft
on follow-up imaging was associated with development of worsening
rejection of the allograft.
The uptake of radiolabeled antibody to class II antigen in the cardiac
allograft correlated with the histological severity of
rejection using either the THI or ISHT gradations (Fig 5
). Despite
highly statistically significant differences in antibody uptake between
these groups, there was significant overlap, particularly in the milder
degrees of rejection. Discrimination between groups appeared to be
better in the presence of more severe rejection; however, the number of
data points within groups was often small. As might have been
anticipated, the relationship between the immunoscintigraphic and
immunohistological findings was closer than with the
standard histological gradation. It has been shown
previously that the upregulation of MHC antigen typically begins before
histological evidence of rejection becomes
obvious.5 Whether this has implications for clinical
imaging is unclear; however, it may allow earlier detection of cardiac
rejection before significant myocyte necrosis occurs.
Study Limitations
The results of this study are encouraging and suggest that this
technique may have potential in the clinical arena. However, there are
several limitations to the present study. First, the main
radioisotope used in this study was 111In chloride. The
optimal time for imaging appeared to be 48 hours after administration
of the radiolabeled monoclonal antibody. At this time, the blood pool
and other background activities were minimal and allowed adequate
visualization of the graft. However, in the clinical setting, this
48-hour wait may be too long and may delay institution of therapy if
significant allograft rejection is present. Second, in this animal
model, the cardiac allograft was located in the cervical region, which
is advantageous for imaging. Imaging a cardiac allograft located within
the thorax would be more problematic, particularly because
of background activity from the liver. However, many of these
limitations could be overcome by the use of a 99mTc-labeled
peptide fragment rather than an intact antibody. The use of a peptide
fragment would result in much more rapid blood clearance, allowing
imaging within several hours rather than a few days, and the use of
99mTc would provide better imaging characteristics than
111In. Third, 1 of the animals studied demonstrated marked
uptake of labeled antibody in the absence of clinical or
histological rejection early after rejection while
receiving full immunosuppression. This was possibly due to pericardial
reaction after surgery. Although it only occurred in 1 of 11 animals,
it does raise concerns about false-positives in the presence of a local
inflammatory reaction when this technique is used. Finally, as eluded
to earlier, due to the expense of this surgical preparation, the number
of animals studied was small, which limited the statistical power of
the study, especially with regard to comparisons between individual
groups.
Conclusions
These data indicate that radiolabeled monoclonal antibodies to MHC
class II antigens can be used to detect and evaluate the severity of
cardiac allograft rejection in this large mammal model of cardiac
allograft transplantation. Our results extend previous findings in a
murine model and suggest that this technique may have a potential role
in detection of rejection in patients after cardiac transplantation,
and it therefore warrants further evaluation.
 |
Acknowledgments
|
|---|
This study was supported by a Grant-in-Aid (No. 93G-273) from
the
American Heart Association, Texas Affiliate, Inc. The authors
would
like to thank Edward T.H. Yeh, MD, for his help with review
and
criticism during the revision of this manuscript.
 |
Footnotes
|
|---|
Guest editor for this article was Barry L. Zaret, MD, Yale University
School of Medicine, New Haven, Conn.
Received March 5, 1997;
revision received April 24, 1997;
accepted May 1, 1997.
 |
References
|
|---|
-
Kriett JM, Kaye MP. The registry of the
International Society for Heart and Lung Transplantation: eighth
official report1991. J Heart Lung
Transplant. 1991;10:491-498.[Medline]
[Order article via Infotrieve]
-
Rose AG. Endomyocardial
biopsy diagnosis for cardiac rejection. Heart
Failure. 1986;2:64-72.
-
O'Connell JB, Bourge RC, Costanzo-Nordin MR, Driscoll
DJ, Morgan JP, Rose EA, Uretsky BF. Cardiac transplantation:
recipient selection, donor procurement, and medical follow-up.
Circulation. 1992;86:1061-1079.[Free Full Text]
-
Billingham ME. Dilemma of variety of
histopathologic grading systems of acute cardiac allograft rejection by
endomyocardial biopsy. J Heart
Transplant. 1990;9:272-276.[Medline]
[Order article via Infotrieve]
-
Rose ML, Coles MI, Griffin RJ, Pomerance A, Yacoub
MH. Expression of class I and class II major histocompatibility
antigens in normal and transplanted human heart.
Transplantation. 1986;41:776-780.[Medline]
[Order article via Infotrieve]
-
Carlquist JF, Hammond E, Yowell RL, O'Connell JB,
Anderson JL. Correlation between class II antigen (DR)
expression and interleukin-2-induced lymphocyte proliferation during
the acute cardiac allograft rejection.
Transplantation. 1990;50:582-588.[Medline]
[Order article via Infotrieve]
-
Isobe M, Narula J, Southern JF, Strauss HW, Khaw BA,
Haber E. Imaging the rejecting heart: in vivo detection of major
histocompatibility complex class II antigen induction.
Circulation. 1992;85:738-746.[Abstract/Free Full Text]
-
Strepkowski S, Raza-Ahmad A, Duncan W. The role
of class I and class II MHC antigens in the rejection of vascularized
heart allografts in mice. Transplantation. 1987;44:753-759.[Medline]
[Order article via Infotrieve]
-
Carrel A, Guthrie CC. The transplantation of
veins and organs. Am J Med. 1905;10:1101-1102.
-
McAllister HA. Histologic grading of cardiac
allograft rejection: a quantitative approach. J Heart
Transplant. 1990;9:277-282.[Medline]
[Order article via Infotrieve]
-
Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe
C, McCallister HA, Snovar DC, Winters GL, Zerbe A. A working
formulation for the standardization of nomenclature in the diagnosis of
heart and lung rejection: heart rejection study group.
J Heart Transplant. 1990;9:5887-5893.
-
Davis WC, Marusic S, Lewin HA, Splitter GA, Perryman
LE, McGuire TC, Gorham JR. The development and analysis
of species specific and cross reactive monoclonal antibodies to
leukocyte differentiation antigens and antigens of the major
histocompatibility complex for use in the study of the immune system in
cattle and other species. Vet Immunol Immunopathol. 1987;15:337-376.[Medline]
[Order article via Infotrieve]
-
Ababou A, Goyeneche J, Davis WC, Levy D.
Evidence for the expression of three different BoLA-class II molecules
on the bovine BL-3 cell line: determination of a non-DR non-DQ gene
product. J Leukoc Biol. 1994;56:182-186.[Abstract]
-
Ababou A, Davis WC, Levy D. The DA6-147
monoclonal antibody raised against the HLA-DRa chain identifies a
cryptic epitope on the BoLA-DRa chain. Ann Rech Vet. 1993;24:402-407.
-
Fraker PJ, Speck JC. Protein and cell membrane
iodinations with a sparingly soluble chloroamide
1,3,4,6-tetrachloro-3
,6
,-diphenylglycouril. Biochem
Biophys Res Commun. 1978;80:849-857.[Medline]
[Order article via Infotrieve]
-
Hnatowich DJ, Childs RL, Lantaigne D, Najafi A.
The preparation of DTPA-coupled antibodies radiolabeled with metallic
radionuclides: an improved method. J Immunol
Methods. 1983;65:147-157.[Medline]
[Order article via Infotrieve]
-
Hall TS, Baumgarter WA, Borkon AM, LaFrance ND, Triall
TA, Norris S, Hutchins GM, Brawn J, Reitz BA. Diagnosis of acute
cardiac rejection with antimyosin monoclonal antibody, phosphorous
nuclear magnetic resonance imaging, two-dimensional
echocardiography, and endocardial biopsy.
J Heart Transplant. 1986;5:419-424.[Medline]
[Order article via Infotrieve]
-
Addonizio LJ, Michler RE, Marboe C, Esser PE, Johnson
LL, Seldin DW, Gersony WM, Alderson PO, Rose EA, Cannon PJ.
Imaging of cardiac allograft rejection in dogs using indium-111
monoclonal antimyosin Fab. J Am Coll Cardiol. 1987;9:555-564.[Abstract]
-
Isobe M, Haber E, Khaw BA. Early detection of
rejection and assessment of cyclosporine therapy in
111In antimyosin imaging in mouse heart allografts.
Circulation. 1991;84:1246-1255.[Abstract/Free Full Text]
-
Takeda K, Ueda K, Scheffel U, Ravert H, LaFrance D,
Baumgartner WA, Reaitz BA, Herslowitz A, Wagner HN.
Indium-111 myosin-specific antibodies and technetium-99m
pyrophosphate in the detection of acute cardiac rejection of
transplanted hearts: studies in a heterotopic heart model.
Eur J Nucl Med. 1991;18:461-466.[Medline]
[Order article via Infotrieve]
-
Frist W, Yasuda T, Segall G, Khaw BA, Strauss HW, Gold
H, Stinson E, Oyer P, Baldwin J, Billingham M, McDougall IR, Haber
E. Noninvasive detection of human cardiac transplant rejection
with indium-111 antimyosin (Fab) imaging.
Circulation. 1987;76(suppl V):V-81-V-85.
-
Ballester M, Obrador D, Carrio I, Moya C, Auge JM,
Bordes R, Marti V, Bosch I, Berna-Roqueta L, Estorch M, Pons-Llado G,
Camara ML, Padro JM, Aris A, Caralps-Riera JM. Early
postoperative reduction of monoclonal antimyosin antibody uptake is
associated with absent rejection-related complications after heart
transplantation. Circulation. 1992;85:61-68.[Abstract/Free Full Text]
-
Conti DJ, Andersen R, Soper WD, Wolf JS.
Comparison of clinical response of DR-matched, MLC-compatible cadaver
renal allografts and those from HLA-identical twins.
Transplant Proc. 1987;19:652-654.[Medline]
[Order article via Infotrieve]
-
Kerman RH, Van Bueren CT, Lewis RM, Frazier OH, Cooley
D, Kahan BD. The impact of HLA A, B, and DR blood transfusions
and immune receptor status on cardiac allograft recipients treated with
cyclosporine. Transplant. 1988;45:333-337.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:

|
 |

|
 |
 
E. Lu, W. R. Wagner, U. Schellenberger, J. A. Abraham, A. L. Klibanov, S. R. Woulfe, M. M. Csikari, D. Fischer, G. F. Schreiner, G. H. Brandenburger, et al.
Targeted In Vivo Labeling of Receptors for Vascular Endothelial Growth Factor: Approach to Identification of Ischemic Tissue
Circulation,
July 8, 2003;
108(1):
97 - 103.
[Abstract]
[Full Text]
[PDF]
|
 |
|